Nostrum Pharmaceuticals, LLC
Records under this name other than patents Nostrum Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Nostrum Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,545,882 | Control release formulation containing a hydrophobic material as the sustained release agent Term ended Term ended Jul 29, 2025 · From the USPTO record | Term ended | Term ended Jul 29, 2025 | From the USPTO record |
| US 8,507,000 | Controlled release formulation of erythromycin derivatives Term ended Term ended May 6, 2024 · From the USPTO record | Term ended | Term ended May 6, 2024 | From the USPTO record |
| US 10,391,419 | Isolation and purification of conjugated estrogens Lapsed on the fee record Ended Aug 27, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2023 | From the USPTO record |
| US 7,897,179 | Pharmaceutical composition containing water soluble drug Lapsed on the fee record Ended Mar 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2023 | From the USPTO record |
| US 6,946,146 | Coating for a sustained release pharmaceutical composition Term ended Term ended Apr 18, 2022 · From the USPTO record | Term ended | Term ended Apr 18, 2022 | From the USPTO record |
| US 6,437,000 | Controlled release oral dosage for suitable for oral administration Term ended Term ended Aug 30, 2020 · From the USPTO record | Term ended | Term ended Aug 30, 2020 | From the USPTO record |
| US 6,635,680 | Controlled release pellet formulation Term ended Ended no later than Aug 30, 2020 · From the USPTO record | Term ended | Ended no later than Aug 30, 2020 | From the USPTO record |
| US 6,416,786 | Sustained release tablet containing hydrocolloid and cellulose ether Term ended Term ended Dec 10, 2019 · From the USPTO record | Term ended | Term ended Dec 10, 2019 | From the USPTO record |
| US 8,906,419 | Pharmaceutical composition containing water soluble drug Lapsed on the fee record Ended Dec 9, 2018 · From the USPTO record | Lapsed on the fee record | Ended Dec 9, 2018 | From the USPTO record |
| US 7,052,706 | Control release formulation containing a hydrophobic material as the sustained release agent Lapsed on the fee record Ended May 30, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2018 | From the USPTO record |